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Abstract
We investigated whether eyedrop vaccination using modified outer membrane vesicles (mOMVs) is effective for protecting
against hemolytic uremic syndrome (HUS) caused by enterohemorrhagic E. coli (EHEC) O157:H7 infection. Modified OMVs
and waaJ-mOMVs were prepared from cultures of MsbB- and Shiga toxin A subunit (STxA)-deficient EHEC O157:H7 bacteria
with or without an additional waaJ mutation. BALB/c mice were immunized by eyedrop mOMVs, waaJ-mOMVs, and mOMVs
plus polymyxin B (PMB). Mice were boosted at 2 weeks, and challenged peritoneally with wild-type OMVs (wtOMVs) at 4
weeks. As parameters for evaluation of the OMV-mediated immune protection, serum and mucosal immunoglobulins, body
weight change and blood urea nitrogen (BUN)/Creatinin (Cr) were tested, as well as histopathology of renal tissue. In order
to confirm the safety of mOMVs for eyedrop use, body weight and ocular histopathological changes were monitored in
mice. Modified OMVs having penta-acylated lipid A moiety did not contain STxA subunit proteins but retained non-toxic
Shiga toxin B (STxB) subunit. Removal of the polymeric O-antigen of O157 LPS was confirmed in waaJ-mOMVs. The mice
group vaccinated with mOMVs elicited greater humoral and mucosal immune responses than did the waaJ-mOMVs and
PBS-treated groups. Eyedrop vaccination of mOMVs plus PMB reduced the level of humoral and mucosal immune
responses, suggesting that intact O157 LPS antigen can be a critical component for enhancing the immunogenicity of the
mOMVs. After challenge, mice vaccinated with mOMVs were protected from a lethal dose of wtOMVs administered
intraperitoneally, conversely mice in the PBS control group were not. Collectively, for the first time, EHEC O157-derived
mOMV eyedrop vaccine was experimentally evaluated as an efficient and safe means of vaccine development against EHEC
O157:H7 infection-associated HUS.
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Introduction
Enterohemorrhagic E. coli (EHEC) can cause severe diarrhea,
hemorrhagic colitis, which is often accompanied by hemolytic
anemia, thrombocytopenia, and acute renal failure, which are the
hallmarks of hemolytic uremic syndrome (HUS) [1]. Although
typical EHEC strains are classified by the production of Shiga
toxin (STx) and the possession of a locus of enterocyte effacement
(LEE) in the chromosome, atypical EHEC lacking LEE pathoge-
nicity islands can be associated with HUS, as recently witnessed in
a German outbreak of E. coli O104:H4 [2]. Despite the lethal
outbreak of HUS due to E. coli O104:H4, EHEC O157:H7
remains the most important causative strain involved in the
manifestation of HUS worldwide [3]. Accordingly, the develop-
ment of effective vaccines preventing EHEC O157:H7 infection-
associated HUS are of prime research interest.
Outer membrane vesicles (OMVs) are spherical membrane
blebs shed by Gram-negative bacteria [4]. They carry not only
native antigens expressed in the outer membrane, but also
exogenous protein epitopes [5] and retain self-adjuvanticity that
can be exerted by the inclusion of toll-like receptor agonists
(lipopolysaccharide [LPS], outer membrane lipoproteins, flagellin,
etc.) [6]. Several reports have demonstrated that vaccination with
OMVs is sufficient to induce an immune response and protect
vaccinated organisms from subsequent pathogen challenge [7–10].
However, up until now, an effective and safe OMV vaccine for
protection from EHEC O157:H7 infection and sequelae HUS has
not been reported, presumably because OMVs generated from
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EHEC O157:H7 are intrinsically toxic due to presence of STx
exotoxin and LPS endotoxin, which are two major virulence
factors that contribute towards the development of HUS. In order
to overcome the toxicity of the EHEC O157-OMVs, we used a
detoxified OMV (produced from MsbB- and STxA-deficient
mutant) that was characterized previously for use as a vaccine
[5,11]. Moreover, we generated waaJ-mOMVs, which were
composed of a truncated version of O157-LPS lacking the O-
antigen side chains, to test whether the absence of O-antigen in
LPS would affect immunogenicity of mOMVs administered via an
ocular-mucosal route.
We found that eyedrop vaccination with mOMVs of EHEC
O157:H7 induced humoral and mucosal immune responses and,
without the use of commercial adjuvants, was able to protect
immunized mice from further challenge with wtOMVs, which are
believed to be produced in the gut of EHEC O157-infected hosts
and have been suggested as the causative agent for HUS [12]. We
also demonstrated that loss of the O-antigen by truncation of
O157-LPS to the core region made waaJ-mOMVs significantly
less immunogenic, indicating the LPS O-antigen in the mOMVs
plays a significant role in inducing a protective immune response
against lethal O157-OMV challenge.
Materials and Methods
Preparation of OMVs of EHEC O157:H7 strains
MsbB- and STxA-deficient mutants of EHEC O157:H7 (Sakai-
DM/stx1A/stx2A) [11] were used as parental strains for producing
mOMVs. The preparation of OMVs has been described
previously [12]. Briefly, a mOMV producing strain was inoculated
in 500 ml of LB broth and cultured with agitation overnight at
37uC. The bacteria were then pelleted by centrifugation
(12,0006g) for 10 min at 4uC. The resulting supernatant was
recovered and further passed through a 0.22 mm pore-size filter.
The mOMVs were harvested by concentrating the filtrates using a
QuixStand ultra-filtration system (GE Healthcare, Buckingham-
shire, UK) equipped with a membrane cartridge (100 kDa cutoff).
Next, mOMVs present in the concentrated sample were collected
and pelleted by ultracentrifugation at 100,0006g for 2 h at 4uC.
The crude mOMV pellet was then resuspended in 3 ml PBS for
further OMV purification using a sucrose-gradient ultracentrifu-
gation step as described previously [5].
Inactivation of the waaJ Gene for the production of
waaJ-mOMVs
An allelic exchange approach was used to facilitate deletion of
waaJ in the chromosome of the mOMV producing strain carrying
pKD46 using a mutant allele (DwaaJ::Cm) constructed in a
pUC18 vector. Briefly, the DwaaJ::Cm allele was constructed by
cloning a genomic DNA fragment (,1.2 kb) encoding the waaJ
ORF. PCR primers used for amplification of the waaJ-encoding
DNA region were designated Fw-WaaJ (GAATTGAAA-
GAATTCGGCTATACATATC) and Rv-WaaJ (GATTTG-
GAAGCTTGGTACGCTGAGCAA C), and the resulting DNA
product was further manipulated by digestion with EcoRI and
HindII restriction enzymes (underlined in the primer sequences,
respectively) for insertion into the pUC18 vector digested with the
same enzymes. The resulting waaJ-pUC18 clone was used as a
template DNA for subsequent inverse PCR to delete an internal
430-bp DNA fragment from the waaJ ORF cloned in pUC18.
Inverse PCR was then carried out with WaaJ-SalF (GTATTTA-
TACTATAAA GTCGACAATTTGAAG) and WaaJ-KpnR
(GATTGAGGTA CCGCCTTCAATGGCTC) primers to delete
the 430-bp DNA fragment and to generate restriction enzyme
(SalI and KpnI) sites (underlined, respectively) at both ends of the
amplicon. Next, the Cm-cassette from pKD3 DNA obtained by
PCR with the FKD3-Sal and RKD3-Kpn primer set [12] was
digested with SalI and KpnI, and was used to replace the 430-bp
Figure 1. Separation of LPS molecules extracted from mOMV
and waaJ-mOMV producing strains. (A) Lanes 1 and 2, silver-
stained LPS samples extracted from mOMV producing strains (MsbB-
and STxA-deficient mutant of EHEC O157:H7) and waaJ-mOMV
producing strains (EHEC O157:H7-waaJ mutant), respectively. Because
of the introduction of the DwaaJ::Cm mutation into mOMV producing
strain, LPS from waaJ-mOMV was uniformly truncated (lane 2) due to
lack of attachment of the O157-antigen polymer compared with the
mOMV producing strain (lane 1). (B) Lack of WaaJ protein (an a-1,2-
glucosyltransferase involved in the LPS core biosynthesis [13]) confers
the EHEC O157:H7 strain with truncated LPS consisting of lipid A with a
core oligosaccharide extended to the galactose residue. The lipid A
portion of LPS lacks the secondary myristate chain (red-colored) of the
mOMV producing strain due to a MsbB deficiency (lipid A acyltransfer-
ase [15]).
doi:10.1371/journal.pone.0100229.g001
Figure 2. Characterization of modified OMVs isolated from
EHEC O157:H7 mutants. (A, B) EHEC O157:H7-derived mOMVs were
characterized by TEM and immunoblot (IB) analysis. The two mOMVs
(mOMV and waaJ-mOMV) visualized by TEM exhibited the expected
shape and size, suggesting that waaJ-mOMVs with uniformly truncated
LPS were more heterogeneous than mOMVs. (C) IB analysis of OMVs
with monoclonal antibodies (anti-STx2A and anti-STx2B) revealed that
the mOMVs (lane 2) were STxA-deficient, but retained STxB subunits
compared to the OMVs of parental Sakai-DM strain (lane 1), which
produces less endotoxic form of LPS [5].
doi:10.1371/journal.pone.0100229.g002
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deleted region of the waaJ gene. The resulting DwaaJ::Cm allele
was introduced into the mOMV-producer strain carrying pKD46
by electroporation to create the DwaaJ::Cm mutant of the
mOMV-producer strain, which was designated EHEC
O157:H7-waaJ. The resulting mutant (EHEC O157:H7-waaJ)
was cultivated to produce the waaJ-mOMV, which contains a
truncated (rough) LPS due to loss of WaaJ activity and is required
for LPS core oligo-saccharide extension [13].
Western Blot Analysis
Protein concentrations of OMV samples were estimated using
the BCA protein assay kit (Pierce, Rockford, IL) and samples were
analyzed by SDS-PAGE (15% gel). Gels were then transferred to a
nitrocellulose membrane (Invitrogen, Carlsbad, CA) for Western
blot analysis. Monoclonal antibodies against STx2B (Biodesign,
Saco, ME) and STx2A (clone 11E10; Santa Cruz Biotech, Dallas,
TX) were purchased from a commercial source. Peroxidase-
conjugated rabbit anti-mouse IgG (Sigma-Aldrich) was used as the
secondary antibody for ECL detection of target proteins.
Negative Staining for Electron Microscopy
To visualize OMVs, samples were applied to a formvar-coated
grid by adsorption. The grid was then stained with 2% uranyl
acetate, blotted with filter paper, and dried in air. Samples were
then examined under a CM20 TEM microscope (Philips, the
Netherlands).
LPS Preparation and SDS-PAGE Analysis
LPS was prepared on a small scale using the SDS-proteinase K
treated whole-cell lysate method adapted from Hitchcock and
Brown [14]. Briefly, bacteria were grown on LB plates overnight.
Cells were then scraped from the plates, resuspended in PBS, lysed
in buffer containing 2% SDS, 4% b-mercaptoethanol, and 1 M
Tris (pH 6.8), and boiled for 10 min. The resulting lysates were
then treated with proteinase K for 60 min at 60uC followed by a
hot-phenol extraction. The phenol-phase containing most of the
LPS was recovered, and LPS was precipitated by the addition of
methanol and chloroform (1:2 v/v) followed by centrifugation.
The LPS pellet was then suspended in distilled water (DW) or SDS
sample buffer and stored at 220uC until use. LPS was separated
on a 16% Tricine SDS-PAGE gel (Novex, San Diego, CA) and
visualized by silver staining.
Animals
This study was performed in strict accordance with the
recommendations in the Guide for the Care and Use Committee
of Yonsei University Health System. The committee has reviewed
and approved the animal study protocol (Approval No: 2011–
0261). Specific pathogen-free BALB/c mice, aged 6–10 weeks,
were purchased from Charles River Laboratories (Orient Bio,
Sungnam, Korea) and were maintained under specific pathogen-
free conditions in the experimental facility at Yonsei University
Health System where they received sterilized food and water ad
libitum. All surgeries were performed after sacrificed by CO2
narcosis and every effort was made to minimize suffering.
Immunization with mOMVs and waaJ-mOMVs
For ocular immunization, five mice were anesthetized and
10 mg mOMVs or waaJ-mOMVs suspended in 10 ml PBS were
dropped on the conjunctival sac of each eye by micropipette. Two
weeks after vaccination, mice were boosted by the same method.
In additional experiments, 10 mg mOMVs plus 10 mg polymyxin
B (PMB) suspended in 10 ml PBS were immunized.
Sample Collection
After intraperitoneal injection of mice with pilocarpine
(500 mg/kg body weight; Sigma-Aldrich), saliva was obtained.
Tear and vaginal wash samples were obtained by lavage with
10 ml or 50 ml PBS. Serum was obtained by tail venipuncture.
Figure 3. Eyedrop vaccination of mOMVs and waaJ-mOMVs
resulted in both systemic and mucosal immune responses.
Groups of BALB/c mice received 10 mg of the mOMVs or waaJ-mOMVs
resolved in 5 ml PBS or PBS by eyedrop on both eyes twice at a 2-week
interval. mOMVs and waaJ-mOMVs-specific antibody titers were
measured by ELISA in serum and in various mucosal secretions at 2
weeks after final vaccination. Results are representative of three
independent experiments, with five mice in each experimental group.
*p,0.05, **p,0.01, ***p,0.001 compared with the PBS group.
doi:10.1371/journal.pone.0100229.g003
Figure 4. Eyedrop vaccination of mOMVs plus PMB blocked
immune responses in mice. Groups of mice given the 10 mg of
mOMVs alone or plus 10 mg of PMB resolved in 5 ml of PBS by eyedrop
on each eye twice at a 2-week interval. mOMVs- (A) or Anti-LPSO157-
specific antibody titers (B) were measured by ELISA in serum or in
various mucosal secretions at 2 weeks after final vaccination. Results are
representative of three independent experiments, with five mice in
each experimental group. **p,0.01, ***p,0.001 compared with the
PBS group; 1p,0.05, 111p,0.001 compared with mOMV-vaccinated
group.
doi:10.1371/journal.pone.0100229.g004
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Fecal extracts were obtained by adding weighed feces to PBS
containing 0.1% sodium azide followed by vortexing. The mixture
was then centrifuged and the supernatants were collected.
Indirect Enzyme-Linked Immunosorbent Assay (ELISA)
ELISA plates (Falcon, Franklin Lakes, NJ) were coated with
mOMVs, waaJ-mOMVs, and wtOMVs, respectively, in PBS and
incubated overnight at 4uC. Blocking was performed with 1% BSA
(Sigma-Aldrich) in PBS, and 2-fold serial sample dilutions were
applied to plates. HRP-conjugated goat anti-mouse IgG or IgA
(Southern Biotechnology Associates, Birmingham, AL) was added
to each well and incubated overnight at 4uC. A tetramethylbenzi-
dine solution (Moss, Pasadena, MD) was used for color develop-
ment. Plates were measured at 450 nm using an ELISA reader
(Molecular Devices, Sunnyvale, CA) after the addition of stopping
solution (0.5 N HCl).
Protection Assay against Wild-Type OMVs
Four weeks after eyedrop immunization with mOMVs, 1.5X
LD50 of wild-type EHEC O157:H7 OMVs (LD50 0.274 mg/kg)
[11] were injected intraperitoneally for the challenge experiment.
Body weight changes were monitored daily for 8 days after
injection. For serum sampling by puncturing the retro-orbital area,
mice were anesthetized by intraperitoneal injection of ketamine
(100 mg/kg body weight) and xylazine hydrochloride (10 mg/kg
body weight) and serum was obtained daily for 8 days. Blood
samples were analyzed for BUN and Cr. For histopathological
observation of kidney, a survived mouse from each group was
sacrificed on day 4 post challenge. All challenged mice were
allowed to proceed to death as a direct result of the wtOMV
challenge (we could not employ humane endpoints because it was
hard to anticipate accurate death point based on only bodyweight
changes, BUN and Cr values. Actually, unvaccinated mice
suddenly died with gradual bodyweight loss but acute increase of
BUN and Cr values) and all survived mice after the protection
assay was finished were sacrificed by CO2 narcosis.
Histology
Eye tissues including the conjunctiva and eye balls from PBS
control and mOMV-treated mice or whole kidney tissues from
wtOMV challenged mice were washed with PBS and fixed in 4%
formaldehyde for 24 h at 4uC. The tissues were dehydrated by
gradual soaking in alcohol and xylene gradients followed by
embedding in paraffin. Paraffin-embedded specimens were cut
into 5-mm sections and stained with H&E.
Safety Evaluation
In order to confirm the safety of vaccinations, some groups of
BALB/c mice were administered with 10 mg of mOMVs or
wtOMVs resolved in 5 ml of PBS by eyedrop on each eye or 10 mg
of wtOMVs resolved in 100 ml of PBS intraperitoneally. Body
weight changes were monitored on a daily basis for 5 days. Eye
tissues were acquired at 24, 48, 72 h after administration of 10 mg
of mOMVs for histologic examination.
Statistical Analysis
All data are expressed as the mean 6 SD. Statistical analyses
were performed by t–tests (Sigma plot).
Figure 5. Eyedrop vaccination of mOMVs can protect vaccinated mice from wtOMVs challenge. For the protection assay, groups of
BALB/c mice vaccinated with 10 mg of the mOMVs resolved in 5 ml PBS or PBS by eyedrop on both eyes twice at a 2-week interval. At 2 weeks after
final vaccination, mice were injected with 1.5X LD50 of wild-type EHEC O157:H7 OMVs (LD50 0.274 mg/kg) intraperitoneally. Body weights (A) and
survival rates (B) were monitored daily. For the measurement of BUN (C) and creatinine (D) levels as indicators of mouse renal function, serum
samples were acquired from all challenged mice daily. (E) For the assessment of renal failure by histological observation, kidney tissues were sampled
from survived mice of each group at 4 days post challenge and stained with H&E staining (original magnification6100). Results are representative of
three independent experiments, with five mice in each experimental group. *p,0.05 versus PBS-vaccinated group.
doi:10.1371/journal.pone.0100229.g005
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Ethics Statement
All experiments involving animal subjects were conducted in
strict accordance and adherence to relevant national and
international guidelines regarding animal handling as mandated
by the Institutional Animal Care and Use Committee (IACUC) of
Yonsei University Health System (Seoul, Korea).
Results
Separation of LPS Molecules Extracted from mOMV
Producing Strains
Characteristic molecular patterns of LPS were visualized by
SDS-PAGE separation and silver-staining of samples extracted
from mOMV and waaJ-mOMV producing (EHEC O157:H7-
waaJ) strains. Because of the DwaaJ::Cm mutation, LPS of the
waaJ-mOMV producing strain was uniformly truncated (lane 2,
Figure 1A) due to lack of attachment of the O157-antigen polymer
compared to LPS of the mOMV producing strain (lane 1,
Figure 1A). Likewise, the lipid A portion of LPS lacked a
secondary myristate chain (red-colored) in the mOMV producing
strain due to deficiency of MsbB activity (lipid A acyltransferase
[15], Figure 1B). Similarly, loss of WaaJ activity (an a-1,2-
glucosyltransferase involved in the LPS core biosynthesis [13])
rendered the waaJ-mOMV producing strain with truncated LPS
consisting of lipid A with the core oligosaccharide extended to the
galactose residue (Figure 1B).
Characterization of EHEC O157:H7-Derived mOMVs and
waaJ-mOMVs
Next, EHEC O157:H7-derived mOMVs were characterized by
TEM and immuno-blot (IB) analyses. Comparison of the shape
and size of the two mOMV types suggested that the waaJ-mOMV
(Figure 2B) containing a uniformly truncated LPS was more
heterogeneous in size formation than that of mOMV (Figure 2A).
IB analysis of both mOMV types with monoclonal antibodies
(anti-STx2A and anti-STx2B) showed that mOMVs were STxA-
deficient but retained STxB subunits (lane 2, Figure 2C). To
confirm the immunogenicity of the STxA-deficient mOMVs, we
vaccinated mice with the mOMVs intramuscularly and it showed
significant increase of total IgG anti-mOMV antibody production
in mice (Figure S1).
Systemic and Mucosal Antibody Responses
To assess the immunogenicity of eyedrop mOMVs and waaJ-
mOMVs vaccination, groups of mice were administered with
mOMVs and waaJ-mOMVs by eyedrop instillation. As shown in
Figure 3, serum IgG Ab and mucosal IgA Ab levels in all
vaccinated mice were significantly increased than PBS group.
Although the levels of both total Ag-specific IgG and IgA Ab of
mOMVs vaccinated mice were not significantly higher than that
of waaJ-mOMVs vaccinated mice, mOMVs immunization
induced slightly higher Ab production levels than waaJ-mOMVs
vaccination (Figure 3). These results indicate that the LPS O-
antigen in mOMVs may serve as a strong immunogenic
component capable of eliciting an antibody response towards
eyedrop mOMVs vaccine. Furthermore, induction of significant
enhancement of systemic IgG and mucosal IgA antibody
production by vaccination of eyedrop mOMVs alone without
any addition of adjuvant suggested that mOMV nano-particles
could be effective vaccination vehicles by providing major antigens
(LPS and outer membrane proteins) in their native form without
additive adjuvants. Additionally, the formation of serum IgG
antibodies cross-reactive to wtOMVs was confirmed in both
mOMVs and waaJ-mOMVs vaccinated groups, and there was
significantly higher level of mOMVs-specific antibody that cross-
reacted to wtOMVs, but not in the waaJ-mOMVs group (Figure
S1).
In this respect, we next evaluated whether premixing mOMVs
with polymyxin B (PMB), which is known as an endotoxin
neutralizing drug, would decrease the immunogenic potential of
mOMVs. As shown in Figure 4, PMB treatment significantly
down-regulated the levels of serum IgG and mucosal IgA Ab in
mice vaccinated with eyedrop mOMVs (Figure 4A). However, the
levels of LPS-specific antibodies were not changed after the
addition of PMB (Figure 4B). These results suggest that the LPS
component of mOMVs administered via the eye mucosa can serve
not only as a vaccine antigen itself, but also a natural form of
strong adjuvant within mOMV vesicle.
Protection Efficacy Assessed for Eyedrop Vaccination of
the mOMVs
To assess the vaccine efficacy of eyedrop immunization of mice
with mOMVs, a challenge experiment was performed by
intraperitoneal injection of lethal dose (1.5X LD50) of wtOMVs.
Mice vaccinated with mOMVs exhibited a slight loss of body
weight (Figure 5A) and were completely protected from challenge
with wtOMVs compared to the PBS control group (Figure 5B).
We next analyzed BUN and Cr levels in serum of challenged mice.
The serum levels of BUN and Cr in the mOMVs-vaccinated
group were not significantly elevated compared with the control
Figure 6. Safety evaluation of eyedrop mOMVs in mice. Groups
of BALB/c mice were administered with 10 mg of mOMVs or wtOMVs
resolved in 5 ml of PBS by eyedrop on each eye or 10 mg of wtOMVs
resolved in 100 ml of PBS intraperitoneally. (A) Body weight changes
were monitored on a daily basis for 5 days. (B) Eye tissues were acquired
at 24, 48 and 72 h after administration of 10 mg of mOMVs for histologic
examination (H&E, original magnification X100). As a control, PBS was
administrated via eyedrop. *p,0.05, ***p,0.001 between ocular
wtOMV-treated group and intraperitoneally wtOMV-treated group.
doi:10.1371/journal.pone.0100229.g006
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group (Figure 5C and D), and these were consistent with
histological observations of the renal tissues of mice vaccinated
with mOMVs which showed virtually no sign of renal bleeding
compared to that of PBS group (Figure 5E, right panel). Thus,
when results above were considered together, the eyedrop
mOMVs-vaccination induced systemic antibody production
against the components of mOMVs and it binds and neutralizes
peritoneally injected wtOMVs so that Shiga toxins within
wtOMVs were blocked in advance and cleared together with
wtOMVs.
Safety of mOMVs Administered by Eyedrop
Since the LPS components that present in the mOMVs would
have a potential to induce an inflammation in administered eyes of
mice, we checked the possibility of toxicity of eyedrop mOMVs.
Mice were administered with 10 mg mOMVs by eyedrop and were
monitored for several days. As shown in Figure 6, there was no
decrease in body weight (Figure 6A) and no histopathological
changes in eye mucosa (Figure 6B). Surprisingly, the administra-
tion of 10 mg wtOMVs by eyedrop induced no significant
reduction on mice body weight compared to PBS treated mice,
whereas mice that were peritoneally injected with the same
amount (10 mg) of wtOMVs exhibited a severe loss of body weight
and eventually died at 4 days post-injection (Figure 6A). Taken
together, these results suggest that vaccination of eyedrop mOMVs
has no toxic effect on eyes, and eye mucosa is an efficient and safe
vaccine delivery route for inducing protective anti-HUS immunity.
Discussion
We previously showed that OMVs produced from EHEC
O157:H7 Sakai strain carried both Shiga toxins and LPS moieties,
and that these vesicles (wtOMVs) caused HUS-like symptoms in a
mouse model [12]. Thus, OMVs are now recognized as a natural
HUS-causative agent produced within the guts of patients after
infection with EHEC O157. Considering that EHEC O157
bacteria are not invasive, it is interesting to note that no
mechanism other than the proposed OMV package delivery has
been demonstrated for trans-migration of Shiga toxins and the
LPS from the gut lumen of HUS patients into the blood stream
[12]. In this study, we showed that eyedrop vaccination of
mOMVs (engineered to be a safe vaccine) was effective for
preventing HUS pathogenesis in mice challenged with HUS-
causative wtOMVs. Furthermore, we also showed that loss of LPS
O-antigen in the waaJ-mOMVs rendered the vesicles much less
immunogenic, suggesting that the presence of LPS O-antigen in
mOMVs is as an important immunogen for inducing effective
anti-OMVO157 antibodies.
For the development of an effective vaccine against EHEC-
related pathogenicity [16,17], STxB subunit-based immunogens
that have ability to induce anti-Shiga toxin antibodies have been
investigated by several laboratories [18–20]. However, no vaccine
able to prevent EHEC infection and/or STx-mediated HUS for
humans and animals has been reported [18,21]. Accordingly, we
looked into what was involved in the immune reaction among
mOMVs including STx2B. In the preliminary results, we could
not raise detectable anti-STxB antibodies by the mOMV
vaccination, although anti-STx antibody plays an important role
in the prevention of HUS, presumably by neutralizing the toxins
directly. However, the immune responses raised by the mOMV
vaccination could protect the mice from the lethal challenge with
wtOMVs given intraperitoneally. This finding supports our
previous report [12] that STx toxins are mostly enclosed within
the OMVs that carry the cargo from the gut where STx is
produced to the blood stream (kidney targeting). Therefore, it is
likely that anti-mOMV antibodies raised by eyedrop vaccination
can block the spread of the toxin by preventing the OMV
translocation and/or circulation into the blood stream.
Mucosal vaccination has numerous merits and thus has gained a
great deal of attention. Specifically, mucosal vaccination is
potentially more convenient and inexpensive compared with
parenteral vaccines, in that it does not require specialized skill for
administration, and can stimulate secretion of IgA antibodies
capable of neutralizing pathogens at sites of entry into the body
[22]. Heat-labile toxin (LT) of enterotoxigenic E.coli (ETEC) is
well known mucosal vaccine adjuvant; however, intranasal
vaccination with LT-adjuvanted vaccine has raised safety concerns
regarding the nervous system [23]. Mucosal vaccination using an
ocular route [24–26] has been shown to effectively protect host
against diverse array of pathogens [27–30]. Since OMVs of
enterotoxigenic E. coli have been reported to induce protective
immune responses against colonization of ETEC strains in the
murine intestine [31], we attempted to determine whether eyedrop
vaccination of mOMVs from EHEC O157 could effectively
prevent HUS after pathogenic E.coli attack. But eyedrop
vaccination of the mOMVs could not raise enough gut-mucosal
immune responses required for lowering the intestinal colonization
by the EHEC O157. Instead, it could induce protective immune
responses preventing systemic distribution of the STx-containing
OMVs. In the context of local gut-associated mucosal antibody
response, it is worth attempting to test and compare the effects of
mucosal vaccination performed via nasal, sublingual, and oral
routes in the further study. Additionally, enhancing the mucosal
immunity through the addition of optimal adjuvants, the usability
of mOMVs as the effective mucosal vaccine would be more
increased.
The experimental eyedrop vaccine model used in this study was
intended to test whether the mOMV could induce mucosal and/
or systemic immune responses or not, which is enough to protect
the vaccinated animal from the lethal HUS-causative agent
(wtOMVs), for the first time, via ocular route of immunization.
Therefore, the intestinal colonization model was not employed in
this study to evaluate the mOMV-mediated mucosal vaccine
effectiveness against the EHEC O157 infection in the gut. It will
also be interesting to test whether mOMVs derived from the
Sakai-O157 strain can act as an effective vaccine against
heterologous EHEC infections. However, our experiment has
given the prioriy in checking out both the formation of
neutralizing antibody against mOMVs and waaJ-OMVs and the
protection against wtOMVs. Although, the exposure of the R3-
core in the LPS lacking the O157 antigen in the waaJ-mOMV can
elicit the R3-core-specific anti-LPS antibodies that may cross-react
to non-O157 Shiga toxin-producing E. coli (STEC) pathogens
possessed with R3-type LPS core commonly [32], we did not test
this possibility that would be another theme to be pursued in our
further experiment.
In addition to mOMVs, which consist of the much-less
endotoxic LPS (penta-acylated lipid A) and are devoid of STxA
subunits, we tested the immunogenicity of waaJ-mOMVs, which
are devoid of the O-antigen side chains of O157 LPS in the
mOMV backbone. O-antigen truncation of LPS of bacterial
pathogens is often associated with decreased immunogenicity
compared with full-length LPS [33]. But, sometimes, exposure of
the core oligosaccharides with O-antigen truncated LPS is
supposed to provide additional immunogenicity [34]. In the case
of waaJ-mOMVs (Figure 3), O-antigen truncation rendered the
vesicles less immunogenic than the ocular mOMV vaccination
model, suggesting that O-antigen in mOMVs may serve as a
Eyedrop Vaccination Using Modified OMV
PLOS ONE | www.plosone.org 6 July 2014 | Volume 9 | Issue 7 | e100229
strong immunogenic component capable of eliciting an antibody
response towards the mOMV vaccine. Furthermore, PMB
treatment of mOMVs, which was used to block the LPS-mediated
adjuvant activity of mOMVs [35], resulted in a significant
reduction of anti-OMVO157 antibody titers (Figure 4A). Interest-
ingly, the ability for inducing anti-LPSO157 antibody was not
affected by PMB treatment (Figure 4B). Since PMB binding to
LPS of mOMVs by charge-to-charge interactions can block TLR-
4 dependent innate immunity activation pathways [36], it has
been suggested that PMB treatment may decrease the potential
adjuvant activity of LPS within mOMVs administered to the
ocular mucosa. Based on our results, LPS moiety of mOMVs
served as an adjuvant by promoting immunogenicity of vesicle
antigens, but did not contribute towards increased production of
anti-LPS antibodies.
In conclusion, eyedrop vaccination using mOMVs of EHEC
O157 bacteria demonstrated for the first time that mOMVs are
efficient vaccination tools which do not require additional
adjuvants. Moreover, eyedrop vaccination with mOMVs was
shown to be effective for preventing HUS pathogenesis in mice
against challenge with HUS-causative wtOMVs. We also demon-
strated that loss of LPS O-antigen of waaJ-mOMVs rendered
vesicles much less immunogenic compared to mOMVs. Thus,
taken together, these results suggest that mOMVs can be utilized
as a safe ocular-mucosal vaccine capable of inducing a protective
immune response against HUS-causative OMVs of EHEC O157
bacteria.
Supporting Information
Figure S1 Eyedrop vaccination of mOMVs resulted in
wtOMVs cross-reactive Ab production. Groups of BALB/c
mice received 10 mg of the mOMVs or waaJ-mOMVs resolved in
10 ml PBS or PBS alone by eyedrop on both eyes twice at a 2-week
interval. wtOMVs cross-reactive antibody titers were measured by
ELISA in serum at 2 weeks after final vaccination. Results are
representative of three independent experiments, with five mice in
each experimental group. *p,0.05 compared with the PBS group.
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